USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: VIDASYM, INC.
Address: 1673 CEDAR GLEN DR
LIBERTYVILLE, IL 60048-3924
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $715,056.00 3
STTR Phase I $458,863.00 2

Award List:

New drug Vida-5 for treating chronic kidney disease progression

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jinshyun R. Wu-wong – 847-863-9818
Award Amount: $219,123.00
Abstract:
DESCRIPTION (provided by applicant): Twenty-six million people in America have chronic kidney disease (CKD). Anemia, cardiovascular diseases, secondary hyperparathyroidism, renal osteodystrophy and other complications are common in CKD. Current treatmentsincluding ACE inhibitors for CKD patients… More

Novel drug VS-105 for treatment of diabetic nephropathy

Award Year / Program / Phase: 2012 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF CHICAGO
Principal Investigator: Jinshyun R. Wu-wong – 847-260-8432
Award Amount: $159,647.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Twenty-six million people in America have chronic kidney disease (CKD). Diabetes is by far the leading cause of CKD (diabetic nephropathy), accounting for 44% of new cases of dialysis (in 2005). Current treatments including ACE inhibitors for CKD patients mainly… More

New drug VS-501 for treating hyperphosphatemia in chronic kidney disease

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jinshyun R. Wu-wong – 847-260-8432
Award Amount: $217,354.00
Abstract:
DESCRIPTION (provided by applicant): Twenty-six million people in America have chronic kidney disease (CKD). Despite the various treatments available to CKD patients, the five-year survival rate is ~33%. Inadequately controlled serum phosphate levels in CKD can lead to various pathologies of… More

New drug VS-110 for treating inflammatory bowel diseases

Award Year / Program / Phase: 2013 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF CHICAGO
Principal Investigator: Jinshyun R. Wu-wong – 847-260-8432
Award Amount: $299,216.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Inflammatory bowel diseases (IBD) involve chronic inflammation of all or part of the digestive tract. Symptoms may include abdominal pain, severe diarrhea and malnutrition. IBD primarily includes ulcerative colitis (UC)and Crohn's disease (CD). In the West,… More

Clinical Development of a Stable Glucagon Formulation for Bi-hormonal Pump

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jinshyun R. Wu-wong – 847-260-8432
Award Amount: $278,579.00
Abstract:
DESCRIPTION (provided by applicant): Osteoporosis is a major public health threat. National Osteoporosis Foundation estimated that the US national direct expenditures for osteoporotic hip fractures were at 17 billion in 2005 and it would increase to 25billion in 2025. Current treatments for… More